Abstract: The present invention relates to novel sulfoperoxycarboxylic acid compounds, and methods for making and using them. The sulfoperoxycarboxylic compounds of the invention are storage stable, water soluble and have low to no odor. Further, the compounds of the present invention can be formed from non-petroleum based renewable materials. The compounds of the present invention can be used as antimicrobials, and bleaching agents. The compounds of the present invention are also suitable for use as coupling agents.

Abstract: The present invention relates to compositions including peroxyacetic acid and peroxyoctanoic acid and methods for preventing microbial growth in aqueous streams including the step of applying a composition of the invention to the stream. The compositions and methods can control microbial growth in aqueous streams used for transporting or processing food products.

Abstract: It is an object to provide an antiviral agent that can be used for persons having sensitive skin or on the face, inactivates viruses such as a norovirus and an influenza virus, and is excellent in germicidal properties. Further provided is a cleansing agent that does not lead to environmental pollution since the cleansing agent is easily decomposed in the natural environment, scarcely causes eczema and allergic dermatitis since no germicidal agent is added, and has an antiviral performance. The antiviral agent containing a surface-active agent having a C18 unsaturated alkyl group as an active component. It is not always necessary to lather or rinse off with water like cleansing agents such as medicated soaps since the antiviral agent of the present invention at a very low concentration can inactivate the virus.

Abstract: An antimicrobial coating system, a film-forming composition, and an antimicrobial film. In some embodiments, the antimicrobial coating system can include a film-forming composition comprising a polymer having an effective molecular weight, and an effective amount of an antimicrobial agent dispersed within the polymer. The film-forming composition can form a water-insoluble, biocidal antimicrobial film when applied to a surface.

Abstract: The present invention relates to the identification of an intranucleosomal DNA loop formed during transcription through a nucleosome and use of the same to identify an agent that modulates the RNA Polymerase II-histone surface.

Abstract: The present invention provides a novel compound and antidepressant composition that can be effectively used for improving depressed mood and depressed state, particularly for depressed mood and depressed state in menopausal women. The compound of the present invention is represented by the following formula (1): wherein R1 and R2 are identical or different and represent a hydrogen atom, a hydroxyl group or an acetyloxy group, and n is an integer of 2 to 7, or a pharmaceutically acceptable salt or ester thereof. This compound is used as an active ingredient in the antidepressant composition. Examples of the compound of the invention include (2E)-9,10-dihydroxy-2-decenoic acid, (2Z)-9,10-dihydroxy-2-decenoic acid, (2E)-9-hydroxy-2-decenoic acid, and (2E)-7-acetoxy-2-heptenoic acid.

Abstract: The present invention relates to a method for preventing obesity later in life by administering a certain nutritional composition to an infant with the age between 0 and 36 months. The composition comprises linoleic and alpha-linolenic acid.

Abstract: The present application relates to compositions comprising and methods of using a liposome comprising a pHLIP polypeptide, wherein a lipid bilayer of the liposome is substantially free of the pHLIP polypeptide.

Abstract: Provided are novel methods and formulations for enhancing feed efficiency and reducing mortality in food animals.

Abstract: A synergistically heat stable therapeutically active triglyceride and cholesterol controlling oil composition including the usually highly unsaturated Eicosa Pentaenoic Acid (EPA) and Docosa Hexaenoic Acid (DHA). The invention avoids limitations of presently available impure sources of EPA/DHA such as fish oil, algae and the like and provides for a synergistically stable edible oil formulation involving the Eicosa Pentaenoic Acid and Docosa Hexaenoic acid of at least 50% to less than 100% purity in a free of any encapsulated/protected form in combination with synergistically stability contributing oil constituents/ingredients. The invention also provides for benefit applications/uses of the surprising and unexpected heat stability of the beneficial actives EPA and DHA. The invention is therefore directed to serve in possible provision of variety of alternative media including heat stable media for regular consumption of EPA/DHA and provide for maintenance of safe and healthy lifestyle.

Abstract: The present invention relates to a condiment comprising an emulsion of an aqueous phase and an oil or fat phase, the emulsion comprising a potato protein protease inhibitor isolate. The invention further relates to a method for preparing a condiment according to any of the preceding claims, comprising preparing an aqueous phase comprising the protein protease inhibitor isolate and thereafter dispersing the oil or fat phase in the aqueous phase or dispersing the aqueous phase in the oil or fat phase.

Abstract: A composition and method are described for sanitizing or otherwise treating a material such as a non-living surface, living tissue, soil or atmosphere which may be contaminated by a toxin, chemical warfare agent, insect, prion, microorganism or other infectious agent. Also described are methods of making the composition.

Abstract: The invention discloses a novel compound effective in inactivating viruses and bacteria. The compound, 2-(10-mercaptodecyl)-propanedioic acid or salts thereof, is shown to disrupt, break down or inactivate viruses and bacteria, thus suppressing infection and proliferation thereof in host cells. A method of chemically synthesizing the novel compound is also disclosed.

Abstract: The invention presented in this application relates to a fragrance deposition system for high surfactant applications such as shampoo and body wash. The system will provide a long lasting release of the fragrance and is more efficient at low levels and does not deposit particles that can cause adverse properties.

Abstract: The teachings herein are directed to antibacterial and anti-inflammatory pharmaceutical compositions that include myristic acid. Further embodiments herein are directed to methods of administering sufficient amounts of myristic compositions to patients in need thereof in order to prevent or treat inflammation and/or bacterial infection. Myristic acid has been established to outperform other cetylated fatty acids in treating infection and inflammation, such as 1-TDC which includes cetylated myristic acid. The compositions and methods provided herein can further be used with additional anti-inflammatory, antibacterial, and delivery agents.

Abstract: The molecules of formula (I) are useful in treating diabetes, obesity, hypercholesterolaemia, hyperlipidaemia, cancer, inflammation or other conditions in which modulation of lipis of eicosanoid status or functions may be desirable. Formula (I): Z1—Z1—Z2 wherein a) Z1 represents CO2H or a derivative thereof; b) Z2 represents F, H, —CO2H or a derivative thereof; and c) X represents fluorinated alkylene; or a solvate thereof, for example a perfluorinated fatty acid or derivative thereof.

Abstract: A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.

Abstract: A natural color is concentrated to intensify color range and to provide useful amounts of one or more of anti-oxidant, nutritional, and anti-inflammatory compounds derived from one or more pigment sources. In a preferred embodiment, the pigment source is a fruit, a vegetable, a legume, a spice, algae, or a combination thereof.

Abstract: The invention relates to a dipeptide conjugate having general formula I, AA2-AA1-NH2, wherein A represent the radical corresponding to a monocarboxylic acid with general formula II, HOOC—R, in which: R represents a linear or branched aliphatic radical at C1-C24, which is optionally substituted by a hydroxyl group and which can comprise one or more unsaturations, preferably between 1 and 6 unsaturations, and/or which can comprise a phenyl group or lipoic acid or the reduced form thereof, dihydrolipoic acid or N-lipoyllysine; and AA1 and AA2 represent identical or different amino acids which are selected from the group containing Ala, Asn, Cys, Gln, Gly, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val, Asp, Glu, Arg, His, Lys, Orn, Dap, Dab, the corresponding homo-amino acids and the corresponding beta-amino acids in the form of enantiomers or diastereoisomers and mixtures thereof, including racemic mixtures.

Abstract: Methods for treating or preventing metabolic dysregulation of adipocytes resulting from HIV-1 infection or chronic inflammation are disclosed. The compositions contain a conjugated fatty acid, a thiol-containing compound and a bioavailable form of trivalent chromium.

Abstract: The present invention relates to fatty acid analogues of the general formula R1-[xi-CH2]n—COOR2 and in particular to a method of treating inflammatory disorder selected from the group consisting of rheumatoid arthritis, systemic vasculitis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, and polymyositis; comprising administering to a mammal in need thereof, an effective amount of tetradecylthioaceticacid or tetradecylselenoacetic acid; or a pharmaceutically acceptable salt thereof.

Abstract: The present invention is directed to stabilized peracid compositions. Stabilizing compositions including a metal salt and a chelating agent are added to compositions including peracids. The results stabilized peracid compositions have increased shelf life and storage stability.

Abstract: Provided is a pharmaceutical composition for permeabilizing fetal membranes including an active ingredient having a log K in the range of 2 to 4, where K is the octanol/water partition coefficient. The active ingredient may be, for example, bupivacaine, sodium lauryl sulfate or oleic acid. Further provided is a system for transfetal membrane transport. The system includes a probe unit adapted for insertion into a female reproductive tract and releasing a substance onto fetal membranes that permeabilizes the membranes. The system is also configured to apply ultrasound radiation to the fetal membranes to further increase the membrane permeability.

Abstract: A method of treating and preventing dyslipidemia, cardiovascular disease, type 2 diabetes, obesity and other diseases associated with the Metabolic Syndrome and of increasing the expression of genes that promote lipid oxidation in an animal, including mammals and humans, in which a therapeutically effective amount of catalpic acid is administered orally or parenterally to the animal.

Abstract: The present invention relates to formulations for animal feed comprising coated granules comprising butyrate salt; the butyrate salt is preferably the salt of sodium or calcium salt. The coated granules have a particle size of 0.1 mm or more, preferably 0.2 mm or more and about 2 mm or less, and preferably about 1 mm or less. The coated granules comprise a binder and a coating. Further, the butyrate salt can be combined with another active ingredient which may be chosen from the group consisting of plant extracts, prebiotic compounds, probiotics, yeast extracts, middle-length chain fatty acids, unsaturated long chain fatty acids, lactate salt, fat soluble vitamin, and toxin absorbing compound.

Abstract: Described is a method of sanitizing animal carcasses using aqueous streams having an antimicrobial composition added to the stream. Preferably, the antimicrobial composition includes a mixture of one or more carboxylic acids having up to 18 carbon atoms and one or more peroxycarboxylic acids having up to 12 carbon atoms, preferably a mixture of a C2-C4 peroxycarboxylic acid and a C8-C12 peroxycarboxylic acid. Also described is a novel antimicrobial composition adapted for sanitizing animal carcasses containing a mixture of one or more C2-C4 peroxycarboxylic acids and one or more C8-C12 peroxycarboxylic acids and an alpha-hydroxy mono- or dicarboxylic acid.

Abstract: Microbial growth inhibiting solutions and methods of employing the microbial growth inhibiting solutions in flushing and coating medical devices are disclosed. In alternative embodiments, the microbial growth inhibiting solutions include combinations of a chelating agent with a C4-C9 carboxylate antimicrobial agent, for example, such as n-octanoic acid. Methods of using these microbial growth inhibiting solutions for coating a medical device and for inhibiting catheter infection are also disclosed.

Abstract: The present invention is concerned with novel cosmetic or pharmaceutical compositions. More particularly, the invention is concerned with novel cosmetic or pharmaceutical compositions for treating or preventing any symptoms caused by negative developments of the physiological homeostasis of healthy skin, as well as for the promotion of hair growth and protection from hair loss.

Abstract: The present invention provides a method for treating wounds and diseases in mammals, caused by mammalian cells involved in an inflammatory response, by altering indigenous in vivo levels of peroxynitrous acid, and salts thereof. The method comprises contacting the mammalian cells with a therapeutically effective amount of a reactive oxygen species mediator, wherein the reactive oxygen species mediator is selected from the group consisting of pyruvates, pyruvate precursors, ?-keto acids having four or more carbon atoms, precursors of ?-keto acids having four or more carbon atoms, and the salts thereof, wherein mediation of reactive oxygen species results in mediation of peroxynitrous acid. The present invention further provides a pharmaceutical composition for treating wounds and diseases in mammals, caused by mammalian cells involved in an inflammatory response, by altering indigenous in vivo levels of peroxynitrous acid, and salts thereof.

Abstract: Methods and devices create an intestinal braking effect, are non-invasive or minimally invasive, and may be reversible. These methods and devices are accomplished via stabilized implantable systems and ingestible pills. In one embodiment, a method of producing satiety comprising the steps of accessing a gastrointestinal tract of a patient and implanting an intraintestinal therapeutic substance eluting implant. The implant is capable of eluting a satiety inducing substance selected from at least one of a nutrient, a specific satiety inducing bio-active substance, pancreatic polypeptides, free fatty acids, cholecystokinin, amino acids, glutamine, lipids, linoleic acid, or a combination thereof, from the implant into the gastrointestinal tract.

Abstract: The invention relates to the use of long chain polyunsaturated fatty acids for the manufacture of a nutritional composition for feeding infants of a mother who suffered from a metabolic disorder during pregnancy and to a corresponding composition. Said composition comprises a n-3 polyunsaturated fatty acid fraction containing at least 0.1 wt docosahexaenoic acid (DHA) based on total weight of the lipid, at least 0.01 wt % n-3 docosapentaenoic acid (DPAn-3) based on total weight of the lipid, and at least 0.01 wt. % eicosapentaenoic acid (EPA) based on total weight of the lipid, wherein the sum of DHA, DPAn-3 and EPA is below 1 wt. % of total lipid.

Abstract: The present invention relates to a medicament which is useful for neurodegenerative diseases, which comprises about 1 to about 5 equivalents of a basic metal ion based on 1 equivalent of (2R)-2-propyloctanoic acid or a salt thereof, which is supplied from a metal salt of weak acid or a metal hydroxide, and optionally further comprises an additive. The medicament of the present invention is a medicament which a pH of suitable for intravenous administration, is resistant to fluctuations of the pH and is not clouded when it is dissolved in an infusion, and an injection and the like can be prepared therefrom by using any dissolving liquid and/or dilution liquid.

Abstract: The invention provides methods of treatment that induce satiety in a subject for a period of at least around twenty-four hours by once-daily administration to the subject of a controlled release dosage form, wherein the dosage form is administered while the subject is in the fasted state and at a time of around six to around nine hours prior to the subject's next intended meal, and wherein the dosage form comprises a controlled release composition, which comprises an enterically-coated, ileum hormone-stimulating amount of a nutritional substance and releases the majority of the nutritional substance in vivo upon reaching the subject's ileum. The invention also provides a diagnostic tool for probing the health and disease state of the ileal hormones, excess or deficiencies. The invention provides a safe vehicle for targeted deliveries of chemical, pharmaceuticals, natural substances and nutrition to the ileum.

Abstract: An invention relates to an extract of Chlorella sorokiniana, which contains myristic acid, palmitic acid, palmitoleic acid, oleic acid, linoleic acid, linolenic acid, and stearic acid. Also related is use of this extract to treat diabetes, obesity, and dyslipidaemia.

Abstract: The novel antimicrobial composition is disclosed including from about 60 to 95% of a lipophilic polar solvent such as propylene glycol, ethylene glycol, or isopropanol and from about 0.5 to 5% of a mixture of C8 to C14 fatty acids. Other constituents of the present invention may include water, an alcohol (such as ethanol or propanol) or a mixture thereof. Also disclosed is a novel method of killing harmful microbes on the udder of a milk-producing animal using the above-mentioned composition.

Abstract: A process for the production of fats or oils and their extracts containing biologically active chemical compounds from a lipid substrate, the process comprising: a) inoculation of a lipid substrate with fungally derived lipolytic enzymes; b) incubating the inoculated substrate for a period of between about 7-120 days at a temperature of between about 435° C., at a humidity of between about 75-100%, and c) processing said substrate mixture to obtain a biologically active fat or oil.

Abstract: A pharmaceutical composition comprising an antisense oligonucleotide and a permeation enhancer that comprises a multi-carbon backbone having a functional group and also one or more side chains which have one or more carbon atoms and, optionally, one or more functional groups.

Abstract: A topical, foamable composition is provided that includes at least one antifungal agent that is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and that has a residual non-volatile component content less than 25%. In addition, a method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis is provided, and includes applying to the affected area of patient requiring such treatment an antifungal composition.

Abstract: One aspect of the invention is a new foam which includes a liquid having a plurality of bubbles therein and a plurality of particles suspended therein. The foam is made in a dispenser that suspends the bubbles in the liquid. The liquid may be a single liquid with particles therein or may be made from two liquids which are mixed together. The particles may be such that, prior to foaming the particles sink, float or are suspended in the liquid.

Abstract: The topical use of 5,6,7-trihydroxyheptanoic acid and analogs alone or in combination with histamine antagonists and/or mast cell stabilizers is disclosed for the treatment of ocular allergy.

Abstract: Disclosed are cosmetic compositions containing a fatty acid, arginine, and a co-emulsifier. Also disclosed are methods for making the cosmetic composition and applying it to keratinous tissue such as skin in order to enhance its appearance.

Abstract: The present invention relates to methods and immunonutritional compositions for preventing the impairment of the immune function during anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently preventing or moderating, bone marrow paralysis or neutropenia of a subject undergoing anti-cancer therapy-induced apoptosis or necrosis or other cell damage such that the innate and adaptive immune functions and normal physiology of the bone marrow are preserved, at least in part, which, in turn, lead to (i) a better tolerance and increased efficacy to anti-cancer therapy; (ii) transient augmentation or enhancement of immunocompetence of the immune cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened by anti-cancer therapy.

Abstract: Compositions for treating or preventing fat maldistribution or hyperlipidemia resulting from anti-retroviral treatment of HIV-1 infection are disclosed. The compositions contain a conjugated fatty acid or alcohol and at least one member selected from the group consisting of a thiol-containing compound and a bioavailable form of trivalent chromium. Methods of treating a subject suffering from HIV-associated fat maldistribution or hyperlipidemia by administering a composition that includes a conjugated fatty acid or conjugated fatty alcohol and at least one member selected from the group consisting of a thiol-containing compound and a bioavailable form of trivalent chromium are similarly provided.

Abstract: The present invention describes systems and methods for treating disorders and/or conditions associated with the dermal level of the skin. Such disorders include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal infection, and/or actinic keratosis. Methods generally involve administering nanoemulsions (e.g., nanoparticle compositions) comprising at least one therapeutic agent, such as botulinum toxin. In some embodiments, nanoemulsions are prepared, e.g., by high pressure microfluidization, and comprise a particle size distribution exclusively between 10 nm and 300 nm.

Abstract: An environmentally safe, pesticidally effective composition is provided to control insect/mite pests. In an exemplary embodiment, a composition is provided that includes a pesticidally effective, yet environmentally safe, concentration of at least one spinosyn with at least one additional contact-acting insecticide and/or miticide and at least one solvent or carrier.

Abstract: A method and chemical composition for modifying and dissolving atherosclerotic plaques formed in a patient's blood vessels is provided. A chemical composition comprising one or more of an organic substance, an inorganic substance, and a bioactive substance is administered at sites of the plaques. The chemical composition comprises one or more of d-limonene, propylene glycol, octanoic acid, 2-octane, glycerine, acetylsalicylic acid, acetic acid, omega-3 fatty acids, ethanol, methanol, ezetimibe, rosuvastatin, resveratrol, lactic acid, gluconic acid, chloroform, carbon disulfide, dichloromethane, toluene, lauryldimethyl hydroxysultaine, and any combination thereof. The chemical composition enables modification of plaques by altering their composition. The modification comprises partial dissolution, complete dissolution, or elimination of the plaques, and makes the plaques amenable to different forms of plaque treatment. The modified plaques are eliminated from the patient's body.

Abstract: Particular aspects provide novel insecticide/miticide/fungicide compositions, and methods for using same for safe, environmentally friendly control of insects, mites and fungal pests in, e.g., gardening and commercial growing. Preferably, the compositions comprise organic or pure ingredients. Particular embodiments comprise: a fatty acid soap base (e.g., saponified soap with retained glycerin; or fatty acid salts with glycerin); at least one essential oil; an optional food oil; and a bicarbonate reagent, along with water. Additional embodiments comprise: a soap base, and/or glycerin or other suitable base; at least one organic or pure plant essential oil; an organic or pure food oil; and a bicarbonate reagent, along with water as diluent and carrier, and methods for using same. Further aspects provide a method for controlling mite and fungal pests with a single composition comprising, along with an aqueous carrier or diluent: a non-petroleum-based food oil; and a bicarbonate agent.

Abstract: The present invention relates to mechanically hemostatic body-absorbable compositions having a putty-like consistency. The compositions preferably comprise a finely powdered, carboxylic acid salt and a liquid block copolymer of ethylene oxide and propylene oxide.

Abstract: The present invention is directed to methods and compounds for inhibiting bacterial growth and treating a bacterial infection in a subject. These methods involve providing an inhibitor of intrabacterial pH homeostasis, including inhibitors of the Mycobacterium tuberculosis Rv3671c gene encoded membrane protease. Methods for identifying novel compounds that disrupt intrabacterial pH homeostasis and their use for inhibiting bacterial growth and treating a bacterial infection in a subject are also disclosed.

Abstract: Nutritional or therapeutic compositions containing glutamic acid, cystine, glycine and a selenium precursor and methods for their utilization to increase glutathione synthesis and thereby enhance the immune system are described.